PHILADELPHIA, Sept. 28, 2023 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg…Original Article
You may also like
Apellis Announces U.S. FDA Approval of the Empaveli...
FDA Approves Technegas (Technetium Tc 99-m Labeled...
FDA Approves Rivfloza (nedosiran) for the Treatment of...
FDA Approves Tofidence (tocilizumab-bavi), a...
U.S. FDA Approves Subcutaneous Administration of...
FDA Approves Bosutinib for Pediatric Patients with...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.